Silence Therapeutics Stock Forward View - Simple Regression
| SLN Stock | USD 5.31 -0.16 -2.93% |
This reference view applies Simple Regression to Silence Therapeutics PLC's historical closing prices. Silence Therapeutics PLC's Simple Regression reference page summarizes the forecasted price and model accuracy metrics from daily trading data. Silence Therapeutics PLC's forecast reference data is generated from the equity's historical trading prices. Mean absolute deviation and related metrics help quantify forecast uncertainty for Silence Therapeutics PLC.
The Simple Regression forecasted value of Silence Therapeutics PLC on the next trading day is expected to be 5.80 with a mean absolute deviation of 0.59 and the sum of the absolute errors of 36.77.In general, regression methods applied to historical equity returns or prices series is an area of active research. In recent decades, new methods have been developed for robust regression of price series such as Silence Therapeutics PLC historical returns. These new methods are regression involving correlated responses such as growth curves and different regression methods accommodating various types of missing data. All forecast values on this page for Silence Therapeutics PLC are Simple Regression reference data derived from historical price series. Simple Regression Price Forecast For the 28th of March
Given 90 days horizon, the Simple Regression forecasted value of Silence Therapeutics PLC on the next trading day is expected to be 5.80 with a mean absolute deviation of 0.59 , mean absolute percentage error of 0.48 , and the sum of the absolute errors of 36.77 .Please note that although there have been many attempts to predict Silence Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Silence Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Silence Therapeutics | Silence Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Silence Therapeutics PLC uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. The current forecast range spans downside near 0.63 and upside near 10.98.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Silence Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Silence Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 119.2204 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.593 |
| MAPE | Mean absolute percentage error | 0.1086 |
| SAE | Sum of the absolute errors | 36.7682 |
Other Forecasting Options for Silence Therapeutics
Volume-weighted price analysis for Silence Stock gives heavier weight to price levels where trading activity was highest. Crossovers in the MACD line and signal line can identify shifts in Silence momentum before they appear in raw price. Comparing Silence Therapeutics' realized volatility to implied volatility reveals whether the options market expects larger or smaller moves. Readings above 80 or below 20 highlight potential reversal zones in Silence Stock price action.Silence Therapeutics Related Equities
These firms work in a similar space as Silence Therapeutics within the Health Care space and serve as useful points for comparison. Market cap and total value checks frame Silence Therapeutics' size within the competitive field. Firms that trade at big discounts to peers on core metrics may be worth more research. Combining quantitative ratios with qualitative context such as management quality and market position sharpens peer comparisons.
| Risk & Return | Correlation |
Silence Therapeutics Market Strength Events
Evaluating the market strength of Silence Therapeutics stock allows investors to gauge shifts in market momentum. Monitoring these indicators highlights periods where Silence Therapeutics PLC trading conditions shift meaningfully. These metrics are particularly useful when Silence Therapeutics stock shows divergence from broader market trends. Regularly reviewing Silence Therapeutics PLC strength signals helps maintain a structured approach to position management.
Silence Therapeutics Risk Indicators
Understanding Silence Therapeutics' risk indicators is essential for any investor seeking to forecast its future price accurately. By identifying how much risk is embedded in Silence Therapeutics' investment, investors can decide how to position their exposure. Reviewing Silence Therapeutics' basic risk indicators is essential for managing investment risk effectively. The risk-return trade-off for silence stock becomes clearer when Silence Therapeutics' risk indicators are properly assessed.
| Mean Deviation | 3.74 | |||
| Standard Deviation | 5.0 | |||
| Variance | 24.98 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Silence Therapeutics
Coverage intensity for Silence Therapeutics PLC matters because narrative visibility can influence sentiment, participation, and volatility around the name. A disciplined read of coverage separates durable relevance from temporary noise.
Contributor Headline
Latest Perspective From Macroaxis
Silence Therapeutics Short Properties
A short-interest review of Silence Therapeutics PLC provides context for understanding whether skepticism in the market is becoming more influential. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 47.2 M | |
| Cash And Short Term Investments | 85.1 M |